Skip to main
TNGX

Tango Therapeutics (TNGX) Stock Forecast & Price Target

Tango Therapeutics (TNGX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 30%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Tango Therapeutics is a promising biotechnology company with a clear focus on precision oncology therapies for various types of cancer. Their pipeline products, particularly PRMT5 and CoREST, have shown promising results in clinical trials, especially in combination with other drugs. The company's potential for success is further strengthened by its partnerships and collaborations, and it operates in a highly competitive market. The recent positive clinical trial data and plans for Phase 3 development have raised our confidence in the company's potential and we have revised our outlook accordingly.

Bears say

Tango Therapeutics is currently not in a favorable financial position, as it requires significant capital to conduct clinical trials and may need to access dilutive and non-dilutive financing. The company also faces potential competition from larger players in the crowded field of KRAS inhibitors, which could hinder its success in the market. Additionally, the recent change in development strategy for its lead product vopimetostat raises concerns about its potential as a monotherapy and in combination therapy with RAS inhibitors. Overall, there are significant financial and competitive risks associated with investing in Tango Therapeutics, making a negative outlook on its stock justified.

Tango Therapeutics (TNGX) has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 30% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tango Therapeutics (TNGX) Forecast

Analysts have given Tango Therapeutics (TNGX) a Buy based on their latest research and market trends.

According to 10 analysts, Tango Therapeutics (TNGX) has a Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tango Therapeutics (TNGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.